BioVaxys and Horizon Finance Finalize Key Asset Agreement Update
BioVaxys and Horizon Technology Finance Corp Amend Asset Purchase Agreement
The APA Formalized the BioVaxys Acquisition of IMV Inc. Assets
BioVaxys Technology Corp. (CSE: BIOV) is excited to inform stakeholders that it has successfully amended the Asset Purchase Agreement (APA) with Horizon Technology Finance Corporation. This APA formalizes the acquisition of a comprehensive portfolio centered around the innovative DPX™ immune educating platform technology, a breakthrough from IMV Inc., a notable name in Canadian biotechnology.
Under the original APA established on February 11, 2024, specific performance milestones were included, notably a requirement for BioVaxys to secure a total capital raise of USD $10 million by a set date. However, following strategic discussions, it was determined necessary to adjust this timeline. Through recent amendments, Horizon and BioVaxys have replaced the initial deadline with a new deadline set for June 30, 2025.
In a subsequent update in May 2025, the parties agreed to further amend the capital raise requirement, reducing it to a net milestone of USD $2,028,636. This change reflects a more attainable target considering the evolving circumstances surrounding the biopharmaceutical industry.
In the most recent amendment dated September 25, 2025, a new adjustment was made to the milestone requirement, reducing the figure further to USD $1,785,625. Should BioVaxys meet this adjusted target by September 30, 2026, the initial terms of Section 12 of the APA will lapse.
Innovative Contributions of BioVaxys Technology Corp.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. is at the forefront of biopharmaceutical innovation, focused on developing novel immunotherapies. Striving to enhance the lives of patients, the company is leveraging its unique DPX™ immune-educating platform and HapTenix© tumor cell construct technology to create impactful solutions. These therapies aim to address various challenges, including cancers, infectious diseases, and food allergies.
The DPX™ platform is particularly noteworthy as it instructs the immune system to foster a targeted, robust response against diseases. BioVaxys boasts an active clinical pipeline, including its lead candidate, maveropepimut-S (MVP-S). Currently in Phase IIB studies, this candidate targets advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer. MVP-S is notable for its ability to activate a specific anti-tumor immune response against survivin, a cancer antigen frequently overexpressed in advanced-stage cancers.
Future Prospects and Developments
Beyond MVP-S, BioVaxys is also pioneering a range of advanced immunotherapies, including DPX™+SurMAGE, designed to target two distinct cancer proteins simultaneously. This dual-targeted approach signifies a shift towards customized treatment pathways in oncology. Other innovative products under development include a respiratory syncytial virus vaccine, an allergy prophylactic, and a personalized therapeutic vaccine for late-stage ovarian cancer.
BioVaxys common shares are publicly traded on the CSE under the stock symbol "BIOV". The company is equally represented on the Frankfurt Bourse (FRA: 5LB) and makes its presence felt in the U.S. markets via OTC Markets (OTCQB). Those interested in learning more about BioVaxys can access the official website for the latest updates and news.
Contact and Responsibility
For any inquiries or further information, please reach out to James Passin, the Chief Executive Officer of BioVaxys. He is available via phone at +1 740 358 0555.
Frequently Asked Questions
What is the recent amendment to the APA between BioVaxys and Horizon?
The recent amendment adjusts the capital raise milestone from USD $2,028,636 down to USD $1,785,625.
Why was the APA originally established?
The APA was formed to acquire the entire portfolio of assets and technology related to the DPX™ immune educating platform from IMV Inc.
What is BioVaxys's primary area of focus?
BioVaxys specializes in developing innovative immunotherapies for cancer, infectious diseases, and allergy treatments.
How can I learn more about BioVaxys?
You can visit their official website for the latest updates and information on their products and research.
Who is the CEO of BioVaxys?
James Passin serves as the Chief Executive Officer of BioVaxys Technology Corp.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.